Actively Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
Led by Ruijin Hospital · Updated on 2024-12-11
40
Participants Needed
1
Research Sites
142 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
CONDITIONS
Official Title
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy according to clinical guidelines
- Signed and dated informed consent form
- Willing to comply with research procedures and complete the full study process
- Aged between 18 and 75 years old
- In good general condition with an expected survival time of more than 6 months
You will not qualify if you...
- Have serious illnesses considered unsuitable for this study, such as severe heart or lung failure, severe bone marrow suppression, or severe liver and kidney dysfunction
- Have intestinal perforation or complete intestinal obstruction
- Uncontrolled diabetes or fasting blood glucose level of 11 mmol/L or higher on the trial day
- Pregnant, breastfeeding, or possibly pregnant women
- Not compliant with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
J
Jiajia Hu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here